本报道最初发表于Endpoints News。请点击这里查看原文
The negative reaction to the impending departure of Sanofi CEO Paul Hudson, and Merck KGaA leader Belén Garijo as his replacement, is perhaps surprising given the French company’s muted performance under Hudson’s leadership.
鉴于韩保罗(Paul Hudson)领导下赛诺菲(Sanofi)业绩平平,人们对其即将离任以及由默克集团(Merck KGaA)负责人贝伦•加里霍(Belén Garijo)接任所作出的负面反应或许令人意外。
您已阅读6%(360字),剩余94%(5716字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。